231 related articles for article (PubMed ID: 17301509)
41. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
42. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
43. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
; Davidson KW; Barry MJ; Mangione CM; Cabana M; Chelmow D; Coker TR; Davis EM; Donahue KE; Jaén CR; Krist AH; Kubik M; Li L; Ogedegbe G; Pbert L; Ruiz JM; Stevermer J; Tseng CW; Wong JB
JAMA; 2022 Apr; 327(16):1577-1584. PubMed ID: 35471505
[TBL] [Abstract][Full Text] [Related]
44. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
45. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
[TBL] [Abstract][Full Text] [Related]
46. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
Kübler W
Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
[TBL] [Abstract][Full Text] [Related]
47. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
48. Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses.
El-Hamamsy MH; Elsisi GH; Eldessouki R; Elmazar MM; Taha AS; Awad BF; Elmansy H
Appl Health Econ Health Policy; 2016 Aug; 14(4):431-440. PubMed ID: 27028445
[TBL] [Abstract][Full Text] [Related]
49. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
[TBL] [Abstract][Full Text] [Related]
51. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study.
Lin KJ; De Caterina R; García Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):70-7. PubMed ID: 24254886
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
[TBL] [Abstract][Full Text] [Related]
54. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
55. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force.
Dehmer SP; O'Keefe LR; Evans CV; Guirguis-Blake JM; Perdue LA; Maciosek MV
JAMA; 2022 Apr; 327(16):1598-1607. PubMed ID: 35471506
[TBL] [Abstract][Full Text] [Related]
56. Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
Dehmer SP; Maciosek MV; LaFrance AB; Flottemesch TJ
Ann Fam Med; 2017 Jan; 15(1):23-36. PubMed ID: 28376458
[TBL] [Abstract][Full Text] [Related]
57. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
58. A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Wu IC; Hsieh HM; Wu MT
BMJ Open; 2015 Jan; 5(1):e006694. PubMed ID: 25575876
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
